Tymlos is owned by Radius Health Inc.
Tymlos contains Abaloparatide.
Tymlos has a total of 5 drug patents out of which 0 drug patents have expired.
Tymlos was authorised for market use on 28 April, 2017.
Tymlos is available in solution;subcutaneous dosage forms.
Tymlos can be used as method of treating postmenopausal women with osteoporosis at high risk for fracture., use for detecting neutralizing antibodies.
Drug patent challenges can be filed against Tymlos from April, 2021.
The generics of Tymlos are possible to be released after 10 January, 2040.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US8748382||RADIUS HEALTH INC||Method of drug delivery for bone anabolic protein|| |
(4 years from now)
|US8148333||RADIUS HEALTH INC||Stable composition comprising a PTHrP analogue|| |
(4 years from now)
|US7803770||RADIUS HEALTH INC||Method of treating osteoporosis comprising administration of PTHrP analog|| |
(8 years from now)
|US10996208||RADIUS HEALTH INC||Abaloparatide formulations and methods of testing, storing, modifying, and using same|| |
(15 years from now)
|US11255842||RADIUS HEALTH INC||Methods for detecting neutralizing antibodies to parathyroid hormone (PTH) and parathyroid hormone-related peptide (PTHRP) analog|| |
(16 years from now)
|New Chemical Entity Exclusivity (NCE)||Apr 28, 2022|
|M||Sep 20, 2024|
NCE-1 date: April, 2021
Market Authorisation Date: 28 April, 2017
Treatment: Method of treating postmenopausal women with osteoporosis at high risk for fracture.; Use for detecting neutralizing antibodies
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic